BACKGROUND: Liver surgery for perihilar cholangiocarcinoma (PHC) is associated with high rates of morbidity and mortality. OBJECTIVES: This study investigated the impact of low skeletal muscle mass on short- and longterm outcomes following hepatectomy for PHC. METHODS: Patients included underwent liver surgery for PHC between 1998 and 2013. Total skeletal muscle mass was measured at the level of the third lumbar vertebra using available preoperative computed tomography images. Sex-specific cut-offs for low skeletal muscle mass were determined by optimal stratification. RESULTS: In 100 patients, low skeletal muscle mass was present in 42 (42.0%) subjects. The rate of postoperative complications (Clavien-Dindo Grade III and higher) was greater in patients with low skeletal muscle mass (66.7% versus 48.3%; multivariable adjusted P = 0.070). Incidences of sepsis (28.6% versus 5.2%) and liver failure (35.7% versus 15.5%) were increased in patients with low skeletal muscle mass. In addition, 90-day mortality was associated with low skeletal muscle mass in univariate analysis (28.6% versus 8.6%; P = 0.009). Median overall survival was shorter in patients with low muscle mass (22.8 months versus 47.5 months; P = 0.014). On multivariable analysis, low skeletal muscle mass remained a significant prognostic factor (hazard ratio 2.02; P = 0.020). CONCLUSIONS: Low skeletal muscle mass has a negative impact on postoperative mortality and overall survival following resection of PHC and should therefore be considered in preoperative risk assessment.
BACKGROUND: Liver surgery for perihilar cholangiocarcinoma (PHC) is associated with high rates of morbidity and mortality. OBJECTIVES: This study investigated the impact of low skeletal muscle mass on short- and longterm outcomes following hepatectomy for PHC. METHODS:Patients included underwent liver surgery for PHC between 1998 and 2013. Total skeletal muscle mass was measured at the level of the third lumbar vertebra using available preoperative computed tomography images. Sex-specific cut-offs for low skeletal muscle mass were determined by optimal stratification. RESULTS: In 100 patients, low skeletal muscle mass was present in 42 (42.0%) subjects. The rate of postoperative complications (Clavien-Dindo Grade III and higher) was greater in patients with low skeletal muscle mass (66.7% versus 48.3%; multivariable adjusted P = 0.070). Incidences of sepsis (28.6% versus 5.2%) and liver failure (35.7% versus 15.5%) were increased in patients with low skeletal muscle mass. In addition, 90-day mortality was associated with low skeletal muscle mass in univariate analysis (28.6% versus 8.6%; P = 0.009). Median overall survival was shorter in patients with low muscle mass (22.8 months versus 47.5 months; P = 0.014). On multivariable analysis, low skeletal muscle mass remained a significant prognostic factor (hazard ratio 2.02; P = 0.020). CONCLUSIONS: Low skeletal muscle mass has a negative impact on postoperative mortality and overall survival following resection of PHC and should therefore be considered in preoperative risk assessment.
Authors: D Gomez; P B Patel; C Lacasia-Purroy; C Byrne; R P Sturgess; D Palmer; S Fenwick; G J Poston; H Z Malik Journal: Eur J Surg Oncol Date: 2013-10-23 Impact factor: 4.424
Authors: Louis M Revenig; Daniel J Canter; Maxwell D Taylor; Caroline Tai; John F Sweeney; Juan M Sarmiento; David A Kooby; Shishir K Maithel; Viraj A Master; Kenneth Ogan Journal: J Am Coll Surg Date: 2013-10 Impact factor: 6.113
Authors: Nuh N Rahbari; O James Garden; Robert Padbury; Mark Brooke-Smith; Michael Crawford; Rene Adam; Moritz Koch; Masatoshi Makuuchi; Ronald P Dematteo; Christopher Christophi; Simon Banting; Val Usatoff; Masato Nagino; Guy Maddern; Thomas J Hugh; Jean-Nicolas Vauthey; Paul Greig; Myrddin Rees; Yukihiro Yokoyama; Sheung Tat Fan; Yuji Nimura; Joan Figueras; Lorenzo Capussotti; Markus W Büchler; Jürgen Weitz Journal: Surgery Date: 2011-01-14 Impact factor: 3.982
Authors: Francesco Landi; Emanuele Marzetti; Anna M Martone; Roberto Bernabei; Graziano Onder Journal: Curr Opin Clin Nutr Metab Care Date: 2014-01 Impact factor: 4.294
Authors: T M van Gulik; J J Kloek; A T Ruys; O R C Busch; G J van Tienhoven; J S Lameris; E A J Rauws; D J Gouma Journal: Eur J Surg Oncol Date: 2010-11-27 Impact factor: 4.424
Authors: Aakash Chauhan; Michael G House; Henry A Pitt; Attila Nakeeb; Thomas J Howard; Nicholas J Zyromski; C Max Schmidt; Chad G Ball; Keith D Lillemoe Journal: HPB (Oxford) Date: 2010-12-07 Impact factor: 3.647
Authors: Wilmar de Graaf; Krijn P van Lienden; Sander Dinant; Joris J T H Roelofs; Olivier R C Busch; Dirk J Gouma; Roelof J Bennink; Thomas M van Gulik Journal: J Gastrointest Surg Date: 2010-02 Impact factor: 3.452
Authors: Thomas A Aloia; Bridget N Fahy; Craig P Fischer; Stephen L Jones; Andrea Duchini; Joseph Galati; A Osama Gaber; R Mark Ghobrial; Barbara L Bass Journal: HPB (Oxford) Date: 2009-09 Impact factor: 3.647
Authors: R J S Coelen; M J de Keijzer; R Weijer; V V Loukachov; J K Wiggers; F P J Mul; A C W A van Wijk; Y Fong; M Heger; T M van Gulik Journal: Cancer Gene Ther Date: 2017-04-14 Impact factor: 5.987
Authors: Pim B Olthof; Robert J S Coelen; Jimme K Wiggers; Marc G H Besselink; Olivier R C Busch; Thomas M van Gulik Journal: HPB (Oxford) Date: 2016-02-18 Impact factor: 3.647
Authors: L B Van Rijssen; N C M van Huijgevoort; R J S Coelen; J A Tol; E B Haverkort; C Y Nio; O R Busch; M G Besselink Journal: Ann Surg Oncol Date: 2016-09-08 Impact factor: 5.344
Authors: Linda B M Weerink; Anouk van der Hoorn; Barbara L van Leeuwen; Geertruida H de Bock Journal: J Cachexia Sarcopenia Muscle Date: 2020-03-03 Impact factor: 12.910